Zai Lab logo

Zai Lab

ZLAB | NASDAQ
Chart Builder DCF Calculator
$23.47
-$1.13 (-4.59%)
At close: Nov 16, 2026, 4:00 PM ET
$23.47
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.59%

Rating

Updated: Nov 16, 2026
44.4
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #409/1021 (Top 40%)

Key Statistics

Market Data

Market Cap $2.65B
1D Range
22.97 24.42
52W Range
16.30 27.00

Valuation (TTM)

PE -12.35
PB 4.70
EV/EBITDA -12.76

Valuation (NTM)

Forward PE 424.50
Forward PEG -0.65
Price Target $35.00
Loading financial charts...

Profile

Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their...

Sector Healthcare
Industry Biotechnology
Employees 1,784
IPO Date Sep 20, 2017
Fiscal Year January - December

Latest News

Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice

16 hours ago · seekingalpha.com

Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

3 days ago · businesswire.com

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces Participation in Investor Conferences in November 2026

3 days ago · businesswire.com

Zai Lab Announces Participation in Investor Conferences in November 2026
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

3 days ago · benzinga.com

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript

3 days ago · seekingalpha.com

Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing

3 days ago · businesswire.com

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?

6 days ago · zacks.com

Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Zai Lab Q3 Earnings Call Highlights

10 days ago · marketbeat.com

Zai Lab Q3 Earnings Call Highlights
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

12 days ago · zacks.com

Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.41
Beat +30.72%
REV
$108.21M
Beat +0.29%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$35.00
Upside
+49.13%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.